AUTHORS
Ruichi Li, Li Wang III, MD2, Zhong Zheng3, Pengpeng Xu, MD4, Shu Cheng, MD5, Wei Li Zhao III, Certified Doctor6
AFFILIATIONS
1 Shanghai Institute of Hematology, State Key Laboratory of Medical Genomics, National Research Center for Translational Medicine at Shanghai, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China, Shanghai, China
2 Shanghai Institute of Hematology, State Key Laboratory of Medical Genomics, National Research Center for Translational Medicine at Shanghai, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China, Shanghai, China
3 Shanghai Institute of Hematology, State Key Laboratory of Medical Genomics, National Research Center for Translational Medicine at Shanghai, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China, Shanghai, China
4 Shanghai Institute of Hematology, State Key Laboratory of Medical Genomics, National Research Center for Translational Medicine at Shanghai, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China, Shanghai, China
5 Shanghai Institute of Hematology, State Key Laboratory of Medical Genomics, National Research Center for Translational Medicine at Shanghai, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China, Shanghai, China
6 Shanghai Institute of Hematology, State Key Laboratory of Medical Genomics, National Research Center for Translational Medicine at Shanghai, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China, Shanghai, China
ABSTRACT
Background
Follicular lymphoma (FL) is the most common indolent non-Hodgkin lymphoma. Chemoimmunotherpy is a SOC for first-line FL with complete response (CR) rates of up to 73% but is associated with significant toxicities. Chemo-free regimens like R2 offer similar efficacy and a more favorable safety profile, highlighting the need for treatments that can induce deeper and more durable responses. The second generation anti-CD20 monoclonal antibody, Obinutuzumab, is approved and demonstrates superior progression-free survival (PFS) compared to first-generation CD20 antibodies in patients with de novo FL. Zanubrutinib is a potent, specific, and irreversible second-generation covalent BTK inhibitor and has demonstrated favorable efficacy in combination with Obinutuzumab in relapse/refractory FL.
Aims
To improve the prognosis of FL patients with multiple high-risk factors at the time of initial treatment, we therefore launched this single-arm, phase II trial to assess the efficacy and safety of obinutuzumab, lenalidomide, and zanubrutinib (ZGR) in treatment-naïve, high-risk (FLIPI2 score 3-5) FL patients (NCT06549335).
Methods
Eligible adults (≥18 years) with newly diagnosed grade 1–3a FL and FLIPI-2 scores 3–5 received induction of ZGR (obinutuzumab 1,000 mg intravenously on days 1, 8, and 15 of cycle 1 and day 1 of cycles 2–6; lenalidomide 25 mg orally days 2–11; and zanubrutinib 160 mg orally twice daily continuously). Maintenance consisted of obinutuzumab and lenalidomide. The primary endpoint was overall response rate (ORR) after induction; secondary endpoints included CR rate, duration of response (DOR), PFS, and 2-year overall survival (OS).
Results
In this study, 60 patients had been enrolled (median age 61 years, range 33–80). All presented with advanced Ann Arbor stage; 78% with Bulky disease; 90% with bone marrow involvement, 44 % had elevated LDH, and 57 % had multiple extranodal sites. Among 45 response-evaluable patients, ORR was 89% (40/45) and CR rate was 76 % (34/45). Meanwhile, ZGR regimen demonstrated consistent efficacy across all high-risk subgroups. The most common adverse event was neutropenia (57%). No new toxicities were observed with the combination regimen compared to the individual agents. No patients discontinued treatment due to adverse events. Exploratory monitoring of peripheral blood ctDNA dynamics from baseline (C1) to post-cycle 1 (C2) showed that patients achieving CR/PR experienced a marked and rapid early reduction in ctDNA concentrations compared with those with SD/PD. Peripheral blood ctDNA alterations predominantly involved genes associated with epigenetic regulation. Survival analysis further demonstrated that patients who achieved maxVAF clearance at C2 had longer PFS. Mass cytometry (CyTOF) analysis showed that patients in the CR/PR group had a higher proportion of naïve CD4+ T cells in peripheral blood at baseline. Expansion of activated CD4+ T-cell subsets and upregulation of CCR7 expression were observed after ZGR therapy.
Summary/Conclusion
Lenalidomide, Zanubrutinib plus Obinutuzumab achieve rapid and deep responses in patients with high tumor burden in FL. With a median of 15.5 months of follow up, follow-up is ongoing. The safety profile was manageable and remained consistent with the known toxicities of the individual components. Lenalidomide, Zanubrutinib plus Obinutuzumab regimen is a novel chemo-free therapy suitable for high-risk FL patients.
DISCLOSURES
Li Wang III, MD: No relevant conflicts of interest to declare.